BioLineRx Ltd. (TLV:BLRX)
Israel
· Delayed Price · Currency is ILS · Price in ILA 2.200
+0.100 (4.76%)
May 29, 2025, 5:24 PM IDT
BioLineRx Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 22.34 | 28.94 | 4.8 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | 91.68% | 502.92% | - | - | - | - | Upgrade
|
| Cost of Revenue | 7.84 | 9.26 | 3.69 | - | - | - | Upgrade
|
| Gross Profit | 14.5 | 19.68 | 1.11 | - | - | - | Upgrade
|
| Selling, General & Admin | 22.94 | 29.68 | 31.58 | 11.53 | 5.31 | 4.75 | Upgrade
|
| Research & Development | 8.28 | 9.15 | 12.52 | 17.63 | 19.47 | 18.17 | Upgrade
|
| Operating Expenses | 31.22 | 38.83 | 44.1 | 29.16 | 24.78 | 22.93 | Upgrade
|
| Operating Income | -16.72 | -19.15 | -42.99 | -29.16 | -24.78 | -22.93 | Upgrade
|
| Interest Expense | -8.57 | -9.07 | -2.14 | -1.79 | -0.98 | -1.47 | Upgrade
|
| Interest & Investment Income | 1.55 | 1.82 | 2.01 | 0.69 | 0.28 | 0.24 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.05 | 0.05 | 0.06 | -0.35 | 0.28 | -0.14 | Upgrade
|
| Other Non Operating Income (Expenses) | 21.54 | 18.39 | -10.84 | 5.64 | -1.85 | -5.72 | Upgrade
|
| EBT Excluding Unusual Items | -2.14 | -7.97 | -53.91 | -24.95 | -27.05 | -30.02 | Upgrade
|
| Asset Writedown | -1.26 | -1.26 | -6.7 | - | - | - | Upgrade
|
| Pretax Income | -3.4 | -9.22 | -60.61 | -24.95 | -27.05 | -30.02 | Upgrade
|
| Net Income | -3.4 | -9.22 | -60.61 | -24.95 | -27.05 | -30.02 | Upgrade
|
| Net Income to Common | -3.4 | -9.22 | -60.61 | -24.95 | -27.05 | -30.02 | Upgrade
|
| Shares Outstanding (Basic) | 1,481 | 1,198 | 963 | 774 | 663 | 253 | Upgrade
|
| Shares Outstanding (Diluted) | 1,481 | 1,198 | 963 | 774 | 663 | 253 | Upgrade
|
| Shares Change (YoY) | 47.46% | 24.37% | 24.47% | 16.75% | 162.19% | 72.70% | Upgrade
|
| EPS (Basic) | -0.00 | -0.01 | -0.06 | -0.03 | -0.04 | -0.12 | Upgrade
|
| EPS (Diluted) | -0.00 | -0.01 | -0.06 | -0.03 | -0.04 | -0.12 | Upgrade
|
| Free Cash Flow | -32.38 | -43.93 | -22.72 | -26.37 | -23.67 | -23.21 | Upgrade
|
| Free Cash Flow Per Share | -0.02 | -0.04 | -0.02 | -0.03 | -0.04 | -0.09 | Upgrade
|
| Gross Margin | 64.90% | 67.99% | 23.08% | - | - | - | Upgrade
|
| Operating Margin | -74.85% | -66.18% | -895.65% | - | - | - | Upgrade
|
| Profit Margin | -15.21% | -31.86% | -1262.79% | - | - | - | Upgrade
|
| Free Cash Flow Margin | -144.92% | -151.78% | -473.42% | - | - | - | Upgrade
|
| EBITDA | -14 | -15.7 | -41.67 | -28.5 | -24.07 | -21.99 | Upgrade
|
| EBITDA Margin | -62.67% | -54.25% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 2.72 | 3.45 | 1.33 | 0.65 | 0.7 | 0.93 | Upgrade
|
| EBIT | -16.72 | -19.15 | -42.99 | -29.16 | -24.78 | -22.93 | Upgrade
|
| EBIT Margin | -74.85% | -66.18% | - | - | - | - | Upgrade
|
| Revenue as Reported | 22.34 | 28.94 | 4.8 | - | - | - | Upgrade
|
Updated Nov 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.